Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Satsuma Pharmaceuticals Inc (Satsuma), a subsidiary of Shin Nippon Biomedical Laboratories Ltd, is a development-stage biopharmaceutical company that develops novel treatments for migraine and other debilitating conditions. The company's lead drug candidate STS101 (DHE nasal powder) is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to be self-administered with a pre-filled, single-use, nasal delivery device that targets migraine. Satsuma is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
Suite 340, 4819 Emperor Boulevard, Durham, North Carolina, 27703
Website
www.satsumarx.com
Telephone
1 650 4103200
No of Employees
25
Industry
Pharmaceuticals and Healthcare
Products and Services
| Products |
|---|
| Pipeline |
| STS101 (Dihydroergotamine): Migraine |
Competitor Comparison
| Key Parameters | Satsuma Pharmaceuticals Inc | BioPhysics Assay Laboratory Inc | Celprogen Inc | Azenta US Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Durham | Worcester | Torrance | Burlington |
| State/Province | North Carolina | Massachusetts | California | Massachusetts |
| No. of Employees | 25 | - | - | - |
| Entity Type | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ryoichi Nagata, M.D., Ph.D. | Chief Executive Officer; Director; President | Executive Board | - | - |
| Shunji Haruta, Ph.D. | Director; Chief Operating Officer | Executive Board | 2019 | - |
| David Prichard | Vice President - Manufacturing Operations | Senior Management | - | - |
| Mic Iwashima | Head - Operations; Vice President | Senior Management | - | - |
| Robert Schultz | Senior Vice President; Head - Chemistry, Manufacturing and Controls | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer